Pharmacy Pearls: GLP-1 Receptor Agonists and SGLT2 Inhibitors – Comparison of CV Outcomes

June 29th, 2020 | Pharmacy Pearls•Diabetes

This edition of Pharmacy Pearls compares the CV outcome study characteristics and results for both the glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium glucose cotransporter 2 (SGLT2) inhibitor classes of medications. It also summarizes key points in regard to the newer oral GLP-1 RA, Rybelsus®, as well as a listing of expanded indications for the SGLT2 inhibitor class of medications. As a reminder, the first line approach for the treatment of type 2 diabetes remains metformin + lifestyle. You can view AHP’s best practices for management of type 2 diabetes by clicking here.

As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.

Taking too long?

Reload document

Open in new tab

Download PDF [867.98 KB]

135 Corporate Woods, Suite 320
Rochester, New York 14623-1466

Phone: (585) 758-7823
Fax: (585) 424-1268

Website by:

This is not an offer to purchase or a solicitation of an offer to purchase any securities or interest in Accountable Health Partners, LLC (AHP). An offer will only be made by means of a confidential private placement memorandum and subscription agreement.

ABI Value	Interpretation	Recommendation
Greater than 1.4	Calcification/vessel hardening	Refer to vascular specialist
1.0 - 1.4	Normal	None
0.9 - 1.0	Acceptable	None
0.8 - 0.9	Some arterial disease	Treat risk factor
0.5 - 0.8	Moderate arterial disease	Refer to vascular specialist
Less than 0.5	Severe arterial disease	Refer to vascular specialist

Pharmacy Pearls: GLP-1 Receptor Agonists and SGLT2 Inhibitors – Comparison of CV Outcomes

Pharmacy Pearls: GLP-1 Receptor Agonists and SGLT2 Inhibitors – Comparison of CV Outcomes

GENERAL COVID-19 INFORMATION